Stock listing

Veracyte, Inc.

Selected listing: 12V · DUS · EUR · DE

Veracyte, Inc. (Dusseldorf:12V), Health Technology. Latest release Sep 29, 2026: Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts…

12V:DUSEURDEUpdated October 2, 2026

Ticker: Dusseldorf:12V
Asset type: Stock
Sector: Health Technology
Industry: Medical Specialties
Exchange: Dusseldorf
Currency: EUR

About Veracyte, Inc.

The company specializes in genomic diagnostics, providing innovative solutions to improve patient care. Veracyte focuses on advancing precision medicine through its advanced technologies and products.

Latest news from Veracyte, Inc.

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

September 29, 2026

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

September 28, 2026

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

September 25, 2026

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

September 14, 2026

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 1, 2026

All Veracyte, Inc. news →

Events

Replays

Veracyte, Inc. (VCYT) Q2 2026 Earnings Call
Thu, Jul 30, 2026 · 04:30 PM ET
Watch
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call
Tue, May 05, 2026 · 04:30 PM ET
Watch
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call
Wed, Feb 25, 2026 · 04:30 PM ET
Watch

Research Veracyte, Inc.

Veracyte, Inc. company profile

View the public company page for Veracyte, Inc. on 6ix.

Veracyte, Inc. news

Read company news and market updates connected to Veracyte, Inc..

Veracyte, Inc. investor events

Find investor webinars, events, and replay context for Veracyte, Inc..